ALISO VIEJO, Calif.—RxSight Inc., an ophthalmic medical device company, has priced its initial public offering of 7.35 million shares at a public offering price of $16 per share. The gross proceeds to RxSight from the offering are expected to be $117.6 million, before deducting underwriting discounts and commissions and offering expenses, according to the company’s recent announcement. In addition, RxSight has granted the underwriters a 30-day option to purchase up to an additional 1.1 million shares at the initial public offering price, less underwriting discounts and commissions.
RxSight is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. The RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens (LAL), RxSight Light Delivery Device (LDD) and accessories, is the first and only commercially available intraocular lens (IOL) technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery.
RxSight’s common stock began trading on the Nasdaq Global Market on July 30 under the ticker symbol “RXST.”
J.P. Morgan Securities LLC and BofA Securities acted as joint book-running managers of the offering and as representatives of the underwriters. SVB Leerink also acted as a book-running manager of the offering.